ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 134 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.55 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $467,787 | -9.8% | 68,290 | +36.5% | 0.00% | 0.0% |
Q2 2023 | $518,821 | -29.9% | 50,031 | -45.3% | 0.00% | -33.3% |
Q1 2023 | $739,636 | +10466.2% | 91,426 | +19905.7% | 0.00% | – |
Q3 2022 | $7,000 | -79.4% | 457 | -81.4% | 0.00% | – |
Q2 2022 | $34,000 | -27.7% | 2,456 | -9.4% | 0.00% | – |
Q1 2022 | $47,000 | -6.0% | 2,712 | -20.7% | 0.00% | – |
Q4 2021 | $50,000 | -54.1% | 3,419 | -43.4% | 0.00% | – |
Q3 2021 | $109,000 | +251.6% | 6,042 | +241.5% | 0.00% | – |
Q2 2021 | $31,000 | -92.4% | 1,769 | -89.0% | 0.00% | -100.0% |
Q1 2021 | $407,000 | +32.1% | 16,149 | -66.1% | 0.00% | 0.0% |
Q4 2020 | $308,000 | +1440.0% | 47,633 | +526.8% | 0.00% | – |
Q3 2020 | $20,000 | +400.0% | 7,600 | +204.0% | 0.00% | – |
Q2 2020 | $4,000 | -81.8% | 2,500 | -78.2% | 0.00% | – |
Q4 2019 | $22,000 | +633.3% | 11,451 | +358.6% | 0.00% | – |
Q3 2019 | $3,000 | -92.7% | 2,497 | -86.6% | 0.00% | – |
Q2 2019 | $41,000 | +720.0% | 18,582 | +2086.1% | 0.00% | – |
Q1 2019 | $5,000 | – | 850 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |